#biotech #Convergen #protein aggregation

Convergen Secures Major Funding to Propel Protein Degradation Therapies

In an impactful move for the biotechnology sector, Convergen has successfully closed a $15 million Seed+ financing round, significantly bolstering its endeavors in the treatment of protein aggregation diseases including neurodegenerative disorders like Alzheimer's. The funding, led by Matrix Partners China (MPCi) along with contributions from LAV, BioTrack Capital, and a prestigious biotech fund, marks a pivotal moment for the company's ongoing research and development initiatives.

Background and Objectives

Convergen is focused on pioneering targeted protein degradation (TPD) therapies, a groundbreaking approach that could change the landscape of treatment for pathological protein aggregates responsible for a range of diseases. This financing round comes on the heels of an earlier $10 million seed financing led exclusively by Qiming Venture Partners, underscoring the increasing interest and belief in Convergen’s innovative approach.

The funds raised will be instrumental in further developing Convergen's proprietary degrader platform, which promises to enhance therapeutic options for patients suffering from various neurodegenerative diseases stemming from protein aggregation.

Dr. Jinquan Sun, CEO of Convergen, expressed gratitude towards the esteemed investors, highlighting their confidence in the company's innovative science and vision. He stated, “We have made significant progress in advancing our protein degradation platform. This financing will enable us to accelerate our lead asset toward the clinic while simultaneously pushing our pipeline forward with the goal of providing new therapeutic options for patients.”

Addressing Unmet Medical Needs

Neurodegenerative diseases continue to represent one of the most pressing unmet medical needs globally. As pathologic protein aggregation is central to the development of these conditions, Convergen is well-positioned to make a significant impact in this critical area. The company's scientific founder, Prof. Ting Han, has been instrumental in establishing the proof-of-concept for the TrimTAC degrader technology, which showcases the potential to selectively degrade proteins associated with these diseases.

The first indication of TrimTAC’s capabilities was published in November 2024 in the esteemed journal Cell, underscoring the scientific community's recognition of this novel approach. Not confined to neurodegeneration, TrimTAC technology is also showing promise in effectively degrading various targets linked to autoimmune diseases.

Investors' Confidence in Innovation

MPCi has placed a high value on Convergen's unique position within the targeted protein degradation sector. Their commitment to investing in companies that exhibit high barriers to entry and clear differentiation underscores their belief in Convergen's potential to revolutionize therapeutic solutions. They expressed,